Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma.

<bold>Objectives: </bold>To determine the diagnostic superiority of parametric response mapping of apparent diffusion coefficient (ADCPR) for predicting glioblastoma treatment response, compared to single time point measurement.<bold>Methods: </bold>Fifty post-treatment glioblastoma patients were enrolled. ADCPR was calculated from serial apparent diffusion coefficient (ADC) maps acquired before and at the time of first detection of an enlarged contrast-enhancing lesion on voxel-by-voxel basis. The percentage-decrease in ADCPR and tenth percentile histogram cutoff value of ADC (ADC10) were compared at subsequent 3-month and 1-year follow-ups.<bold>Results: </bold>The percentage-decrease in ADCPR was significantly higher in the progression group (mean = 33.2-38.3 %) than in the stable-response group (mean = 9.7 %) at 3 months follow-up (corrected p < 0.001 for both readers). ADCPR significantly improved area under the receiver operating characteristic curve from 0.67 to 0.88 (corrected p = 0.037) and from 0.70 to 0.92 (corrected p = 0.020) for both readers, respectively, compared to ADC10 at 3-month follow-up, but did not significantly improve at 1-year follow-up. The inter-reader agreement was higher for ADCPR than ADC10 (intraclass correlation coefficient, 0.93 versus 0.86).<bold>Conclusion: </bold>Voxel-based ADCPR appears to be a superior imaging biomarker than ADC, particularly for predicting early tumour progression in patients with glioblastoma.<bold>Key Points: </bold>• Treatment response pattern of glioblastoma was evaluated using voxel-based ADCPR and ADC10. • Voxel-based ADCPR was more accurate in predicting treatment response pattern than ADC10. • Inter-reader agreement was higher in ADCPR calculation than in ADC10 calculation. • Voxel-based ADCPR can be a predictor of early treatment response pattern for glioblastoma. [ABSTRACT FROM AUTHOR]